MMCM
PDLI

Murphy & Mullick Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Murphy & Mullick Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100
Closed – – 746
2026
Q1 		$0 Hold
100
– – ﹤0.01% 799
2025
Q4 		$0 Hold
100
– – ﹤0.01% 838
2025
Q3 		$0 Hold
100
– – ﹤0.01% 690
2025
Q2 		$0 Hold
100
– – ﹤0.01% 712
2025
Q1 		$0 Hold
100
– – ﹤0.01% 697
2024
Q4 		$0 Buy
+100
New – ﹤0.01% 670

Other funds holding PDLI

DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Murphy & Mullick Capital Management's PDLI Position: Q2 2026 in Review

Murphy & Mullick Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q2 2026, closing a stake of 100 shares.

Murphy & Mullick Capital Management first reported a position in PDLI in Q4 2024 and held it in 6 quarters. The position peaked at $0 in Q1 2026. 5 funds tracked by Wall St. Rank hold PDLI as of Q2 2026.

  • Murphy & Mullick Capital Management reported no remaining PDL BioPharma, Inc. position as of Q2 2026 after selling out during the quarter.
  • Murphy & Mullick Capital Management sold 100 PDL BioPharma, Inc. shares in Q2 2026.
  • Murphy & Mullick Capital Management first reported a position in PDL BioPharma, Inc. in Q4 2024 and held it in 6 quarters.
  • Murphy & Mullick Capital Management's PDL BioPharma, Inc. position peaked at $0 in Q1 2026.
  • 5 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.